It has been recognised that vitamin D (VitD) has a potential role in the regulation of inflammation and protection from infection. In a prospective clinical observational pilot study, we investigated the serum levels of 25-hydroxyvitamin-D3 (25(OH D3), 1,25-hydroxyvitamin-D3 (1,25(OH)2D3), parathyroid hormone (PTH), and cathelicidin in intensive care unit (ICU) patients with or without systemic inflammatory response syndrome (SIRS). We included 32 patients with SIRS (septic patients), 16 ICU patients without SIRS, and 16 healthy controls. To substantiate the findings of the clinical study, we stimulated monocyte-derived macrophages with microbial patterns and analysed the impact of VitD on release of cytokines and antimicrobial activity. We found that patients with or without SIRS had relatively low levels of 25(OH)D3 and 1,25(OH)2D3. Patients with sepsis had significantly lower levels of 25(OH)D3 as compared to ICU control patients and healthy controls (10.53 ± 11.3 µg/l versus 16.46 ± 12.58 µg/l versus 24.04 ± 12.07 µg/l); the same was true for 1,25(OH)2D3. Serum levels of PTH and cathelicidin were significantly increased in sepsis patients, as compared to the other groups. In vitro, VitD significantly decreased the release of pro-inflammatory cytokines from macrophages and increased the antimicrobial activity of the cells. We concluded that patients with sepsis have significantly lower VitD levels. In vitro, VitD modulates inflammation and increases the antibacterial activity of innate immune cells. These findings suggest that VitD insufficiency is mechanistically related to increased susceptibility to SIRS and sepsis.
Background
Systemic inflammatory response syndrome (SIRS), sepsis and septic shock are responsible for a significant number of deaths. In a mechanistic view, sepsis and septic shock are the consequence of a dysregulated activation of the body's host defence system in response to microbial stimulation 1 . Despite significant progress in the understanding of the pathophysiology of sepsis, the exact mechanisms, involved cell types and mediators that have a role in the disease development are speculative 2 . Significant progress in treatment has been made; most is related to implementation of basic management algorithms such as fluid resuscitation 3 , early antibiotic treatment 4 , and lung-protective ventilation 5 , although some of these progresses have been questioned by recent data 6, 7 .
Development of sepsis involves numerous events that finally result in a catastrophic breakdown of various organ functions 1 . In the pathological pathway leading to the activation of innate and adaptive immunity, macrophages are sentinel cells of the innate immune system and are capable to sense the presence of small amounts of microbial patterns 8, 9 . We have shown that pulmonary macrophages have a central role in the initiation and orchestration of host defence and inflammation in pneumonia 10 .
Vitamin D (VitD) is one of the oldest evolutionary hormones 12 . In addition to the regulation of calcium homeostasis, it has been recognised that VitD might have a role in the regulation of inflammation and protection from infection 13 . VitD can be obtained from diet or is synthesised in the skin after exposure to ultraviolet B radiation. Ultraviolet light catalyses the first step in the biosynthesis which is the conversion of 7-dehydrocholesterol into the pre-vitamin D cholecalciferol, which is converted to its major circulating form, 25-hydroxyVitD (25(OH)D3) in the liver, and subsequently in the kidney and other organs into its active form, 1,25-dihydroxyVitD (1, 25 (OH)2D3) by 1-hydroxylase (CYP27B1) 14 . 1,25(OH)2D3 mediates its effects by binding to the nuclear vitamin D receptor (VDR), which regulates the expression of a large number of genes. Evidence from clinical investigation, animal models, and cell experimentation indicates that hypovitaminosis D might be involved in the susceptibility to a wide array of human diseases including infection, inflammatory, and neoplastic diseases 15 . The overall and cardiovascular mortality appears to be inversely correlated with serum levels of VitD 16, 17 . Several studies investigated the prevalence of VitD deficiency in intensive care unit (ICU) patients and found that most critically ill patients had very low levels of VitD [18] [19] [20] . Furthermore, VitD deficiency was associated with increased mortality in septic adult [21] [22] [23] and paediatric 24 patients.
The aim of this study was to investigate the role of VitD in SIRS and sepsis. To generate a comprehensive view, we approached this question using a clinical study and experiments at the cellular level using primary macrophages. In a clinical cohort of intensive care patients, we determined the levels of VitD forms in serum and investigated whether patients with SIRS were deficient in VitD as compared to non-SIRS ICU patients. To characterise potentially involved mechanisms, we performed ex vivo experiments and evaluated whether VitD modulates the release of cytokines by innate immune cells or impacts on the cells' antimicrobial activity.
Methods

Clinical study
The study was designed as a prospective cohort pilot study. We included 48 critically ill patients on ICUs of the Marburg University Hospital (one surgical and three medical ICUs) and 16 healthy subjects as controls. Of the ICU patients, 32 were diagnosed as having SIRS as defined by the criteria of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee 25 . The patients were identified by the staff physician and reported to the study team. The underlying diagnoses in the SIRS group were infection of the abdomen (9), the lungs (5), orthopaedic tissues (5), the urogenital tract (3), the endocardium (2), and catheter-associated infection (2) . In six patients the source of infection was unknown. All patients in this group had evidence of systemic infection and thus were septic based on the guidelines of the Surviving Sepsis campaign 26 . Applying the new definition for sepsis 27, 28 to this group, 31/32 patients had a Sequential Organ Failure Assessment (SOFA) score ≥2 (30 had a SOFA score of ≥5); however, these data were derived from the initial assessment within 24 hours after admission and not-as recommended-a change in the SOFA score. As controls, we included 16 healthy subjects (healthy control, HC; no current active disease or medication) and 16 patients on the ICU without the diagnosis of SIRS (diagnoses: acute coronary syndrome (9) , acute left heart failure (2), pulmonary embolism (1), acute renal failure (1), anaphylactic shock (1), implanted cardiac defibrillator malfunction (1), and hypokalaemia (1)) (ICU-C). Fourteen patients in this group exhibited a SOFA score of <2. None of these control patients developed sepsis during the hospital stay. The samples were collected between February 2008 and April 2009. ICU patients were characterised by gender, age, and ICU-scores within 24 hours after admission to the ICU. As ICU-scores we used the Acute Physiology and Chronic Health Evaluation II (APACHE II), the Multiple Organ Dysfunction Score (MOD-Score), and the SOFA. We recorded body temperature, mean arterial pressure, heart rate, breathing rate, pH, sodium, potassium, creatinine, white cell count, platelets, Glasgow Coma Scale, age, chronic health status, PaO 2 /FiO 2 ratio, urinary excretion, bilirubin, dosage of vasopressors, and R/P-Ratio (systolic arterial pressure/pulse ratio). The current medication was recorded; the application and the settings of ventilatory assist or dialysis was also noted. Diagnoses and laboratory data were obtained from patient charts, discharge summaries and computer databases. The study was approved by the ethics committee of the University of Marburg (ID number 119/07) and informed consent was obtained from patients or their legal representative.
Sample collection
Serum samples were collected either through central venous catheters or through arterial catheters. The samples were obtained in blood collection tubes (Sarstedt, Nuembrecht, Germany). Serum for determination of 1,25(OH)2D3 was centrifuged for 20 minutes at 1200 rpm. The serum was stored at -80°C prior to analysis. Serum levels of 1,25(OH)2D3 were assessed by enzymelinked immunoabsorbent assay (ELISA) (ImmunDiagnostik, Bensheim, Germany). Serum levels of 25(OH)D3 were determined by high-performance liquid chromatography (HPLC) (Chromsystems, Munich, Germany) within five days after collection. HPLC is one of the gold standard methods for VitD measurement 29 . Protocols for each assay were per the manufacturer's product manuals. VitD sufficiency was defined as a 25(OH)D3 concentration >30 µg/l, insufficiency was defined as a 25(OH)D3 concentration of 20-30 µg/l, and deficiency was defined as a 25(OH)D3 concentration <20 µg/l. Serum levels of parathyroid hormone (PTH) were measured by a commercially available chemiluminescent immunoassay (Unicel® DxI 800, Beckman Coulter, Fullerton, CA, USA). Serum levels of cathelicidin were determined by ELISA (monoclonal antibody against LL-37/hCAP-18, Clone 1-1c12, Sanbio [Hycult], Germany; horseradish peroxidase [HRP] labelled anti-mouse antibody, GE Healthcare, NA931; synthetic LL-37, Dr. Peter Henklein, Charite, Humboldt-Universität, Berlin, Germany) as described before 30 . mRNA was isolated from total blood using the PAXgene® Blood RNA Kit (QIAGEN, Hombrechtikon, Switzerland) and used for semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) as described earlier 31 .
Ex vivo analysis of VitD effect on macrophages
Human monocytes were isolated via Ficoll density gradient centrifugation from blood products obtained from the blood bank of the University Hospital Giessen and Marburg. Red blood cells were lysed and the remaining cells were counted and analysed for purity by microscopic analysis. Monocytes were cultured in Dulbecco's modified eagle medium (DMEM)-GlutaMax II supplemented with 0.1 mM nonessential amino acids, 10% foetal calf serum (FCS, Invitrogen, ThermoFisher Scientific, San Diego, CA, USA) and 1% penicillin/streptomycin (PAA, Cöelbe, Germany). Differentiation into macrophages was achieved by adding 50 ng/ml macrophage-colony stimulating factor (M-CSF, Calbiochem®, Darmstadt, Germany) for seven days. Macrophages were preincubated with the toll-like receptor (TLR)1/2 ligand Pam3SCK4 (Metabion, Martinsried, Germany) for two hours and then with 25(OH)D3 (40 ng/ml) or 1,25(OH)2D3 (40 ng/ml) (Calbiochem®, Darmstadt, Germany) six hours before stimulation with heat-inactivated Pseudomonas aeruginosa PAO1. Pam3SCK4 is a synthetic triacylated lipopeptide that mimics the acylated amino terminus of bacterial lipopolysaccharide. It acts as a potent activator of the proinflammatory transcription factor NF-κB. The release of cytokines into the culture supernatant was measured using commercial ELISA kits for interleukin (IL)-1beta and tumour necrosis factor (TNF)-alpha (R&D Systems, Wiesbaden-Nordenstadt, Germany).
To test whether cathelicidin modulates the antibacterial activity of macrophages, 10 6 /ml macrophages in 10 ml were stimulated with 10 nM Pam3SCK4 for 24 hours. 25(OH)D3 was added to specific culture media at a concentration of 40 ng/ml. Pseudomonas aeruginosa PAO1 was grown and prepared as described earlier 32 and added to the cells at a cell:bacteria ratio of 1:1. At 0, 15, 30, 45, and 60 minutes, 20 µl of the cell suspension was removed and incubated with 80 µl triton 0.1%, diluted 1:100 in phosphate-buffered saline and plated onto agar plates. Bacterial colonies were counted after incubation.
Statistical analysis
GraphPad Prism version 5.0 software (La Jolla, CA, USA) and MedCalc version 11.1.1.0 were used for all statistical analysis. When the study was planned (2007) valid data to derive a formally correct power calculation were not available; we thus performed the study as a pilot study. D'Agostino and Pearson omnibus normality test was conducted to test for normality. If samples were distributed following Gaussian distribution, one way analysis of variance (ANOVA) with Bonferroni correction was used to test for significant differences between the means of the three described groups. Where samples did not follow Gaussian distribution, the Kruskal-Wallis test with Dunn's correction was used. To test for correlation Spearman's rho was calculated. For binary variables (male/female and survival/non-survival) Fisher's exact test was used. Data are presented as means ± standard deviation (SD) unless stated otherwise.
Results
VitD levels are lower in patients with SIRS, while PTH levels are higher
To investigate whether SIRS patients have deceased serum levels of VitD, the levels of 25(OH)D3 and 1,25(OH)2D3 were measured in SIRS and control patients. The groups were similar in distribution of gender and body mass index. HCs were significantly younger than SIRS patients (51.25 ± 11.5 years versus 64.1 ± 13.8; P <0.01). As expected, SIRS patients exhibited significantly higher ICU-scores (APACHE II, MODS, SOFA) than ICU-C patients and HCs. Baseline characteristics of the subjects are presented in Table 1 . The VitD status of SIRS patients at baseline (day one) differed significantly from ICU-C patients and HCs. SIRS patients exhibited significantly lower levels of 1,25(OH)2D3 than ICU-C patients and HCs ( Figure 1A) . A similar pattern was found for 25(OH)D3 ( Figure  1B) . We used two techniques to correct for dilution potentially caused by fluid resuscitation: we calculated the ratio of VitD levels and total serum protein (and haematocrit) before and after fluid resuscitation in SIRS patients and ICU-C patients.
Using corrected VitD concentrations (protein method and haematocrit method) the significant differences between the groups remained unchanged (data not shown). We analysed whether there were correlations between mortality and VitD levels and found no difference between VitD deficient, insufficient, or sufficient individuals (Table 2) . Lastly, we examined PTH level in all patients: PTH levels of SIRS patients at baseline (day one) were significantly higher than levels from ICU-C patients and HCs (Figure 2 ). In conclusion, these data show that most patients with SIRS have significantly lower VitD levels and higher PTH levels.
Serum levels of cathelicidin are increased in SIRS
VitD is involved in the regulation of expression of cathelicidin, an antimicrobial peptide with direct antimicrobial and immunomodulatory activity 33 expressed in numerous cell types 34, 35 . To investigate whether the serum levels of LL-37/ hCAP-18, the only cathelicidin in humans, are correlated with VitD levels, we determined this parameter by ELISA. Serum levels of cathelicidin protein were significantly increased in SIRS patients compared to ICU-C patients and HCs ( Figure  3A) . The cathelicidin serum levels of ICU-C patients and HCs were nearly identical. The mRNA-level of cathelicidin did not differ between any of the groups (Figure 3B ). The levels of cathelicidin protein in the serum correlated negatively with the concentration of 25(OH)D3 (Spearman's r = -0.39; P <0.005) and 1,25(OH)2D3 (Spearman's r = -0.29; P <0.05).
25(OH)D3 and 1,25(OH)2D3 modulate macrophage functions
To investigate whether VitD directly modulates the activity of macrophages, we performed ex vivo experiments with macrophages derived from human blood monocytes obtained from healthy donors. We incubated monocytederived macrophages with 25(OH)D3 or 1,25(OH)2D3 and determined the release of cytokines after stimulation with TLR ligands. The exposure of macrophages to 25(OH)D3 or 1,25(OH)2D3 resulted in the significant decrease of released IL-1beta and TNF-alpha ( Figure 4A-B ). We next tested whether the antimicrobial activity of macrophages is modulated by 25(OH)D3. We applied a bacterial killing assay and found that 25(OH)D3 induces an increase of direct antibacterial activity ( Figure 4C ). To investigate whether expression of cathelicidin in macrophages is regulated by exposure of the cells to VitD and microorganisms, we determined the transcription of the cathelicidin antimicrobial peptide (CAMP) gene and found that the combination of both stimuli results in its strong induction ( Figure 4D ). These data indicate that VitD modulates the release of pro-inflammatory mediators by activated innate immune cells and augments the direct antibacterial activity of macrophages.
Discussion
The main finding of the present study is that patients with sepsis have lower blood levels of VitD in their blood despite a high PTH level. VitD insufficiency is highly prevalent in all three study populations. In vitro, VitD decreases proinflammatory reactions and augments antimicrobial activity of macrophages. Taken together, these data support the hypothesis that VitD may have a role in susceptibility to the development of sepsis.
Our data confirm and expand other studies on the VitD metabolism in critically ill patients and patients with SIRS and sepsis. We found that ICU patients with or without sepsis had relatively low levels of 25(OH)D3 with significant numbers of patients in the deficiency range. Patients with sepsis had significantly decreased levels of 25(OH)D3 and 1,25(OH)2D3 as compared to the control patients and healthy controls. These data confirm an earlier study of ICU patients, in which critically ill subjects had significantly lower plasma 25(OH)D3 concentrations compared to healthy controls 18 . In contrast to our study, there was no difference between the sepsis and the non-sepsis ICU groups. The results of a prospective study on the VitD status in ICU patients revealed a high prevalence of hypovitaminosis D that was associated with adverse outcomes, independently of hypocalcaemia and hypoalbuminaemia 19 . In the study of Lucidarme et al on critically ill patients, 79% of the included individuals had low levels of 25(OH)D3 <60 nmol/l 20 . While these relatively small studies showed no association with VitD levels and risk of death, large epidemiological studies revealed a link between the cardiovascular and overall mortality and low plasma VitD levels 17 . Interestingly, the incidence of sepsis is highest in seasons with low sun exposure and putatively low serum levels of VitD 36 . Recent studies demonstrated that low 25(OH)D3 levels are correlated with decreased survival in patients in intensive care units [37] [38] [39] [40] [41] underscoring the potential role of VitD in the regulation of inflammation. These studies also demonstrated that patients with sepsis had low levels of 25(OH)D3. While the present study was not designed to detect differences in mortality in patients with sepsis, we determined low levels of 25(OH)D3 in the target population.
One important question is whether low blood levels could be a consequence of severe illness. The serum levels of several vitamins are decreased during an acute phase reaction 42 . One reason for low VitD levels in patients with inflammation under medical treatment could be dilution of serum components by fluid resuscitation 43 . In the present study, levels of 25(OH)D3 and 1,25(OH)2D3 remained low at day three and seven of the study. We measured the levels of serum protein and haematocrit as parameters that indicate fluid dilution. Even after correction for dilution based on the changes of protein or haematocrit between administration and later measurements, concentrations of 25(OH)D3 and 1,25(OH)2D3 were significantly lower in the ICU-C and sepsis groups. One further aspect is that a single measurement of VitD levels might not reflect the 24 hour profile and thus the underlying deficiency state in critically ill patients 44 . This effect is likely less significant when a larger cohort is investigated as positive or negative deviations from an average concentration are likely detected in a random manner. In summary, patients with sepsis have low levels of VitD. This finding does not necessarily prove a causal role of low vitamin levels in the modulation of the susceptibility to sepsis. Because both VitD forms (25(OH)D3 and 1,25(OH)2D3) were low and PTH was high in septic patients we think that a severe PTH deficiency as well as a severe impairment of the PTH-induced 1-hydroxylase is rather unlikely, although this has been suggested analysing similar data and results 41 . Besides its well-established role in calcium and bone metabolism, VitD appears to have a role in modulation of inflammation and immunity. In the present study we showed that VitD has a profound effect on human macrophages. Both 25(OH)D3 and 1,25(OH)2D3 reduce the release of pro-inflammatory cytokines from these cell types after stimulation by microbial patterns. Interestingly, the antibacterial activity of macrophages is increased in parallel. This effect could be potentially relevant in infection and could counteract the cytokine storm and bacterial proliferation. Low serum concentrations of VitD correlate with decreased phagocytic activity of macrophages 45 and 1,25(OH)2D3 is a potent suppressor of interferon-gamma-mediated macrophage activation 46 . Presence of 25(OH)D3 increases the antimicrobial activity of macrophages against M. tuberculosis after stimulation with mycobacterial ligands. Mycobacterial activation of TLR-2 results in expression of VDR and CYP27B and subsequently of the antimicrobial peptide cathelicidin 33, 47 . Also structural cells, such as airway epithelial cells, are able to convert the precursor 25(OH)D3 into the active 1,25(OH)2D3 form 48, 49 . 1,25(OH)2D3 inhibits lipopolysaccharide-induced immune activation in human endothelial cells 50 , a cell type that has been mechanistically involved in the development of sepsis. It down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns 51 . The heterodimerisation of VDR with the vitamin A receptor RXR appears to be particularly irrelevant at the mucosal site 52 .
One possible mechanism of the VitD effect on immunity is the induction of cathelicidin, an antimicrobial peptide that has direct antibacterial and regulatory activities 33, 53 . Cathelicidin is an antimicrobial peptide with pleiotropic activities within an innate immune reaction including activation of wound healing or angiogenesis. In preclinical animal studies the application or overexpression of cathelicidin protects from sepsis [54] [55] [56] [57] . In the current study, we found increased levels of cathelicidin in sepsis patients. The peptide's levels were negatively correlated to the 25(OH)D3 and 1,25(OH)2D3 concentrations. In contrast, two other groups found significantly lower mean plasma LL-37 levels in critically ill subjects, with significant positive association between circulating VitD and cathelicidin levels 18, 58 . The reasons for this discrepancy might be differences in the patient cohorts or in the ELISA methodology. As sepsis and SIRS is associated with recruitment of neutrophils, which likely represent a major source of the peptide, an increase of antimicrobial peptides in septic patients is biologically plausible. Furthermore, neither healthy volunteers 59 nor critically ill septic patients 58 , when supplemented with VitD, did show increased concentrations of hCAP-18 in the blood, indicating that the regulation of cathelicidin expression by VitD is complex. Most likely, the expression of cathelicidins is only partly regulated by VitD but also by other factors such as exposure of cells to microbial structures and inflammatory mediators in the local microenvironment.
There are several limitations of our cohort study that need to be acknowledged. First, the sample size of our cohort is small. Second, all our patients in the SIRS group were apparently septic. Applying the new sepsis definition according to the Sepsis-3 consensus (using a SOFA of ≥2 instead of a change of the SOFA as recommended) did not alter the results significantly. In contrast, the non-SIRS ICU cohort represents a much healthier patient group, that-in many hospitals-would reflect patients on an intermediate care unit. However, we felt that the discrimination in three groups (SIRS, ICU-C, HC) would have the advantage of looking at the whole spectrum of health and disease. Third, blood levels of 25(OH)D3 have been measured using an ELISA rather than liquid chromatography-mass spectometry. However, as the results paralleled with the blood levels of 1,25(OH)2D3, we judge the findings as valid. The strengths of our study are the combination of a clinical observational study with an in vitro study that supports the clinical findings. Furthermore, we expand previously published results by correcting for fluid resuscitation and providing longitudinal data, both to demonstrate that the initial findings were not confounded by the early management of severe SIRS or sepsis.
In conclusion, ICU patients have low levels of 25(OH)D3 and 1,25(OH)2D3 and patients with SIRS or sepsis have even lower levels. Together with the results from the in vitro experiments, these data indicate that the VitD-cathelicidin axis might have an important role in inflammatory and infectious processes.
